Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Strandboulevarden 49, Copenhagen 2100, Denmark.
Department of Gynaecology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen 2100, Denmark.
Br J Cancer. 2018 Feb 20;118(4):611-615. doi: 10.1038/bjc.2017.449. Epub 2018 Jan 9.
Increasing data suggest that aspirin use may improve cancer survival; however, the evidence is sparse for ovarian cancer.
We examined the association between postdiagnosis use of low-dose aspirin and mortality in a nationwide cohort of women with epithelial ovarian cancer between 2000 and 2012. Information on filled prescriptions of low-dose aspirin, dates and causes of death, and potential confounding factors was obtained from nationwide Danish registries. We used Cox regression models to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for ovarian cancer-specific or other-cause mortality associated with low-dose aspirin use.
Among 4117 patients, postdiagnosis use of low-dose aspirin was associated with HRs of 1.02 (95% CI: 0.87-1.20) for ovarian cancer mortality and 1.06 (95% CI: 0.77-1.47) for other-cause mortality. Hazard ratios remained neutral according to patterns of low-dose aspirin use, including prediagnosis use or established mortality predictors.
Low-dose aspirin use did not reduce mortality among ovarian cancer patients.
越来越多的证据表明,阿司匹林的使用可能改善癌症患者的生存状况;然而,关于卵巢癌的证据仍然有限。
我们研究了 2000 年至 2012 年期间丹麦全国上皮性卵巢癌患者队列中,低剂量阿司匹林的诊断后使用与死亡率之间的关系。从全国性的丹麦注册中心获取有关低剂量阿司匹林的处方填写情况、死亡日期和原因以及潜在混杂因素的信息。我们使用 Cox 回归模型估计了低剂量阿司匹林使用与卵巢癌特异性或其他原因死亡率相关的风险比(HR)及其 95%置信区间(CI)。
在 4117 名患者中,低剂量阿司匹林的诊断后使用与卵巢癌死亡率的 HR 为 1.02(95%CI:0.87-1.20),与其他原因死亡率的 HR 为 1.06(95%CI:0.77-1.47)。根据低剂量阿司匹林使用模式,包括诊断前使用或已确立的死亡率预测因素,风险比保持中性。
低剂量阿司匹林的使用并不能降低卵巢癌患者的死亡率。